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ABSTRACT
Research has exposed cancer to be a heterogeneous disease with a high degree 
of inter-tumoral and intra-tumoral variability. Individual tumors have unique profiles, 
and these molecular signatures make the use of traditional histology-based treatments 
problematic. The conventional diagnostic categories, while necessary for care, thwart 
the use of molecular information for treatment as molecular characteristics cross 
tissue types. 
This is compounded by the struggle to keep abreast the scientific advances made 
in all fields of science, and by the enormous challenge to organize, cross-reference, 
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INTRODUCTION
The conventional approaches to cancer therapy have 
been until very recently based on eradicating cancer cells 
by three modalities - surgery, radiation and chemotherapy. 
While this approach improved outcomes for children 
with acute lymphoblastic leukemia where survival rose 
from 20% in the 1950’s to about 95% now, it was much 
less effective in solid tumors and adult leukemias. In 
these more genetically complex cancers, some modest 
initial improvements in survival rates were achieved, 
but even those modest gains have been stagnating since 
the late 90’s. Many different reasons contribute to the 
treatment resistance of solid tumors and adult leukemias, 
but chiefly among those are: 1. the genomic complexity 
and heterogeneity of these entities, and 2. the protective 
effect of the host / tumor microenvironment.[1, 2] Novel, 
molecularly-based treatment modalities target not only 
tumor cells, but also the tumor cell-induced changes in 
the tumor microenvironment. In addition to those agents 
directed against tumor cell epitopes and receptor tyrosine 
kinases, there are monoclonal antibodies directed against 
endothelial growth factors and receptors, inflammatory 
cells and immune surveillance cells. All of those can 
be combined to correct the tumor/ microenvironment 
interaction, and not only sensitize to existing therapies 
but to effectively target the developmental end-stage 
characteristics of tumorigenesis. 
The term biologic agent is therefore quite broad. 
It should be considered synonymous with “biological 
response modifiers”, “targeted agents” or “molecularly-
guided therapies”, as well as with other terms used 
in the broader scientific literature to describe agents 
that target an otherwise physiological biological 
events “hijacked” by the tumor for growth benefit. The 
physiological mechanisms used by tumor cells for 
survival, i.e. inflammation, angiogenesis, immune system 
and regenerative pathways, have not been considered as 
targets in the past, even though wide-ranging spectrum of 
agents exists for their modulation. They include inhibitors 
of growth factor pathways, angiogenesis inhibitors, 
enhancers of pro-apoptotic signals, immune response 
modifiers, adhesion inhibitors, proteasome inhibitors, 
signal transduction inhibitors and any other agents 
targeting a defined biological process in the cancer tissues.
Unfortunately, while all these new insights 
have come to the forefront of cancer science, their 
implementation to clinical practice has been quite slow. 
The understanding that cancer-specific biology may be less 
dependent on the tissue of origin, and more dependent on 
a genomic (molecular) signatures, represents a paradigm 
shift in thinking. This new definition accepts cancer not 
as foreign tissue, but rather as a natural consequence of 
lifelong accumulation of molecular alterations, lending 
credence to therapeutic approach that considers cancer 
a chronic disease. Unlike the present goal of cancer 
eradication in a manner similar to antibacterial therapy; 
scientists now accept that cancer may be managed as a 
lingering chronic illness influenced by the inflammatory, 
immune and angiogenesis phenotype of the host. Scientists 
continue to identify the many molecular lesions that can 
lead to cancer progression and recognize that each tumor 
harbors its own genomic signature.[3] The basic question 
that remains to be answered is which part(s) of the 
molecular signature are related to the primary oncogenic 
event, and which are secondary. 
The traditional picture of a linear evolution of a 
cancer through clonal expansion driven by accumulation 
of sequential mutations inherent to the cancer clone 
has now been nuanced by the influence of tumor 
microenvironment. Most cancers are a mixture of cancer 
cells and normal host cells that have been recruited to the 
site, or that have been induced to action by oncogenic 
changes occurring in cancer cells during malignant 
and apply molecular data for patient benefit. In order to supplement the site-specific, 
histology-driven diagnosis with genomic, proteomic and metabolomics information, 
a paradigm shift in diagnosis and treatment of patients is required. 
While most physicians are open and keen to use the emerging data for therapy, 
even those versed in molecular therapeutics are overwhelmed with the amount of 
available data. It is not surprising that even though The Human Genome Project was 
completed thirteen years ago, our patients have not benefited from the information. 
Physicians cannot, and should not be asked to process the gigabytes of genomic and 
proteomic information on their own in order to provide patients with safe therapies. 
The following consensus summary identifies the needed for practice changes, 
proposes potential solutions to the present crisis of informational overload, suggests 
ways of providing physicians with the tools necessary for interpreting patient specific 
molecular profiles, and facilitates the implementation of quantitative precision 
medicine. It also provides two case studies where this approach has been used.
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transformation. In genetically complex forms of cancers, 
it is difficult to define a specific “driver gene” within the 
multiplicity of gene alterations, unless one can evaluate 
the quorum of signals within the tumor microenvironment. 
A vastly improved ability to establish the hierarchy of 
genomic alterations present in the tumors of individual 
patients will be needed for a correct analysis and 
interpretation of biological information.
Despite the incomplete and continuously amended 
molecular information, and notwithstanding the 
fragmented understanding of its usefulness for effective 
anti-cancer therapies, many molecularly-based therapies 
have been implemented with spectacular success. Yet, as 
the example of imatinib demonstrates, the deployment 
of targeted therapy - from its discovery to standard of 
practice clinical use - can take more than thirty years in 
the present clinical climate.[4] Even in the case of CML, 
a cancer with a single therapeutic target, the traditional 
route to clinical implementation of bcr/abl complex 
inhibitors was uncomfortably slow. The process may 
be streamlined in rare diseases - the use of denosumab 
(inhibitor of RANKL) for the treatment of giant cell tumor 
of the bone - but the implementation of even a single agent 
therapy is filled with trepidations and insurance denials. 
It is therefore not surprising that for those diseases with 
activation of more than one molecular pathway, the 
implementation of molecularly-guided therapy remains 
challenging. 
Therapeutic strategies incorporating inhibition of 
multiple molecular pathways will need to address the 
considerable differences in tumors between individuals, 
the heterogeneity within a single tumor, as well as the 
differences between the primary tumor and its metastatic 
lesions. Numerous and quite comprehensive catalogues 
of somatic mutations obtained by comparing a patient’s 
tumor DNA/RNA sequences to his/her germline DNA/
RNA[5, 6] indicate a great deal of heterogeneity in cancer 
genome evolution across different tumor types, across 
individual patients with the same tumor type, and even 
within a tumor.[7, 8] Considering this heterogeneity, 
the present appeal of enhancing the traditional site- 
and histology-specific treatment protocols with a more 
personalized approach (ie. precision medicine), can be 
more easily understood. 
Scientists[9, 10] and leading politicians[11] have 
recognized that supporting progress toward precision 
medicine and increasing the use of biological therapies 
holds a strong promise of not only improving health 
outcomes,[12] but also of potentially improving cost 
effectiveness of cancer therapies.[13] The concept of 
precision medicine, as heretical as it may have initially 
sounded in cancer therapy, is not foreign in medicine. We 
test for antibiotic sensitivity, and we match blood for HLA 
subtypes in transfusion and transplantation medicine, and 
it is not surprising that our cancer patients are beginning 
to demand the same.[14] Ultimately, effective, precise, 
target-tailored medicines may abolish the use of old-
fashioned cytotoxic treatments, or at least eliminate 
the need for maximum tolerated doses of radiation and 
chemotherapy. The implementation of these new treatment 
modalities will, require a number of necessary changes to 
the oncological practice and research in oncology. We will 
need to:
1. change clinical trial design in order to obtain 
efficacy data from n - 1 trials
2. provide and interpret large data while 
maintaining excellent data integrity
3. develop novel mathematical approaches 
for establishing hierarchy of genomic alterations in 
individual tumor samples
4. provide combination therapies based on pathway 
analyses
5. avoid combinations with maximum tolerated 
doses of chemotherapy: the argument for low dose 
(metronomic) chemotherapy backbone
THE NEED TO CHANGE CLINICAL 
TRIAL DESIGN IN ORDER TO OBTAIN 
EFFICACY DATA FROM N - 1 TRIALS
Medical practice is a conservative vocation, and 
one of the most often repeated quotation in medical lore 
is: Primum non nocere (“first do no harm”). As such, in 
order to facilitate the translation of precision medicine 
to practice, sufficient evidence about precision medicine 
being as good or better than present therapies is requisite 
for the larger scientific and medical community to use 
the therapy. Unfortunately, over the last 40 years various 
regulations, were instituted in order to protect the public 
from unfounded claims of cure. While these were initially 
created for the benefit of the patient, they have led to 
a very inflexible structure of clinical trials - one that is 
no longer optimal for testing of new biological agents. 
Present clinical trials involve the addition of a single 
new agent to standard, established, maximum tolerated 
dose of therapy. To arrive at such a trial, the new agent 
must first go through a dose finding (dose escalating) trial 
(Phase I), which determines its maximum tolerated dose 
(MTD). The need to know the MTD is based on the well 
ingrained notion that the relationship between dose and 
cancer cell kill is linear[15] and more must be better. The 
notion, even though disavowed by the same scientist that 
first introduced it[16, 17], continues to be very dominant 
in oncology, even though some oncologists have begun 
using lower doses of chemotherapy in combination with 
targeted therapies.[18-21]
Once the MTD is defined in Phase I trial, the agent 
is put through an early efficacy trial (Phase II), before 
proceeding to a randomized, double blind, placebo-
controlled (Phase III) trial to validate its efficacy, and to 
post-marketing surveillance studies (Phase IV). While 
Phase I-IV trials were informative for evaluation of the 
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conventional surgery/chemotherapy/radiation approach, it 
is not optimal for biological agents where optimal dose 
is not the MTD and where toxicities are minimal.[22] 
This particular point is further discussed in section 5.1, 
and represented graphically in the Figure 1. Phase I-IV 
clinical trial design may not only be unsuitable for testing 
biological agents, they may be detrimental to the testing of 
biologically based therapies because most biologic agents 
sensitize to chemotherapy and radiation, and thus heighten 
the toxicity in the combination arms.[23, 24] 
A body of pre-clinical and clinical evidence indeed 
suggests that the relationship between the dose of a 
biologic agent and its effect is NOT linear.[25, 26] It is 
most commonly U-shaped. One of the earliest publications 
suggesting this phenomenon showed that the effect of 
interferon alpha 2B differed at low, medium and high 
doses[27] (see Figure 1A). This was subsequently found 
to be true for most biologic agents, especially those that 
depend on receptor/ligand interaction. Once all receptors 
are engaged, and the full effect achieved, any further 
increase in dose leads to off-target effects rather than 
further receptor inhibition. The excess of drug therefore 
intensifies toxicities. For example, while the effect of TGF 
beta1 at low doses is anti-tumorigenic, its effect at higher 
levels is pro-tumorigenic, creating a U-shaped response 
curve (see Figure 1B).[28] This characteristic u-shaped 
response curve of biological agents, termed hormensis,[26] 
further illustrates that levels and function of biological 
agents influence the equipoise of several pathways, and 
can be tumor suppressive or tumor promoting.
The doses of biological agents should therefore 
be determined by the optimal biologically effective 
Figure 1: The U-shaped curve associate with the effect of biological therapies. Unlike the linear relationship between dose and 
cell kill assumed in the early work of Skipper and Schabel15 - the effect of a biologic agent may differ at low and high doses. Panel A is an 
adaptation of figure first published by Slaton23 in 1999. The optimum biologically effective dose is often a medium rather than maximum 
dose. This U-SHAPED CURVE may facilitate the initial up and the subsequent down-regulation during physiological biological processes. 
In a stress response a linear increase of interleukins is desired during the initial stress, but a relaxation needs to follow in presence of excess 
ligand. 
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dose, rather than by a maximum tolerated dose, and the 
Phase I/II trials are not suitable for the introduction of a 
biological agent to clinic. In the case of biologic agents 
more is not necessarily better, and dose escalations using 
the traditional Phase I trial may not only be inappropriate, 
they can be detrimental, because the effect of the 
biological agent at high doses may be opposite to the 
desired effect.[25, 26] The change in pharmacodynamics 
of metronomically dosed vinblastine vs MTD vinblastine 
provides a very good example. The dose of vinblastine 
used for inhibition of angiogenesis is many folds lower 
than the anti-proliferative dose of vinblastine (~6mg/m2).
[29]
The fact that Phase I trials are in general meant to 
establish dose-limiting toxicities rather than offer therapy 
is something most patients may not be able to appreciate 
when a Phase I trial is presented to them as the “last 
option”. The chance of cure or even of a positive response 
is very small, especially in situations where the intended 
target is not tested for and may not even be present. While 
some early efficacy trials of targeted agents for relapsed 
cancers may show some effectiveness,[30] the response is 
rarely sustained. 
The role of a randomized, double-blind placebo 
controlled trial (RCT) is similarly questionable in an 
era where precision medicine is available. An RCT is in 
principle a comparison of two populations, one with and 
the other without the tested agent. Its goal is to find an 
agent that would be effective for the largest percentage of 
the general population, rather than optimize therapy for an 
individual. Because identifying the best treatment for an 
individual is so fundamentally different from a treatment 
that performs best at the population level, it is highly 
unlikely that Phase III approaches will be able to capture 
the outcomes of targeted therapies in precision medicine. 
There is an early level of recognition of the need to 
revise the present model of clinical trials. Timely changes 
to clinical practice have been suggested by the recent 
National Cancer Institute Precision Medicine Initiatives 
for the new National Clinical Trials Network,[31] but 
most molecular testing continues to be used only as means 
to streamline the enrollement in clinical trials. In order 
to accommodate the n = 1 trial model, early discussions 
have been initiated about creation of a “cancer knowledge 
network”,[10] where information from the numerous 
case studies of truly individualized cancer treatments 
could be shared and evaluated. A case in point is the 
early effort to collect data from patients using targeted 
therapies in the NCI-Molecular Analysis for Therapy 
Choice (NCI-MATCH) Trial. In this trial, which opened 
in August 2015, analyzes patients’ tumors to determine 
whether they contain genetic abnormalities for which a 
targeted drug exists (that is, “actionable mutations”) and 
assigns the patient to a clinical trial based on one of the 
detected abnormalities. While the trial will make some 
data available, its limitation lies in its traditional trial 
design. The trial suffers from two shortcomings; one, it 
is likely that of the hundreds of patients tested, only very 
few will find a matching clinical trial, and two, even 
though the tumor tissues will be analyzed for more than 
4,000 different variants across 143 genes, patients with 
more than one genomic abnormality will still be enrolled 
on a single agent therapy trial, ignoring the actual tumor 
biology. This approach does not change the paradigm, 
as it does not address the complexity of tumor biology, 
heterogeneity and especially not the need for pathway 
analysis in cancer therapy.
A special problem in clinical studies is the 
current practice to include at first instance only relapsed 
and refractory patients. As mentioned, malignant 
cell proliferation is under control of the primary 
oncogenic event, but secondary (acquired) changes may 
independently control further malignant cell proliferation. 
The chance that analysis of tumors in newly diagnosed 
patients may elucidate the basic oncogenic driver(s) and 
the respective pathway(s) is much more likely. In this 
respect, newly diagnosed patients with cancers where the 
prognosis is poor should be considered for individualized 
therapies before resorting to the present standards. In 
children with poor prognosis disease, a well designed 
up-front window therapy, would clarify response to 
biological agent(s) more clearly. Examples where these 
studies should be considered are children with metastatic 
sarcoma, brain tumors or neuroblastoma where up 80% 
of children die despite elaborate standard chemotherapy 
and radiation protocols. To identify the basic oncogenic 
driver(s), all newly diagnosed malignancies would need 
additional molecular analysis as mentioned below. 
A POTENTIAL SOLUTION
To remedy the difficulty of collecting individual 
case study data we propose formation of consortium(s) of 
pediatric and adult institutions providing a standardized 
approach to selection of targets aided by computer 
assisted information processing and facilitated through 
an online tumor board review. The outcomes of the 
individual cases within the consortium(s) can then be 
pooled, evaluated, and used to inform selection of targets 
for future patients in real time (Figure 2). It is unlikely 
that all collaborative groups will be able to use the same 
tissue biomarker analysis outside a collaborative clinical 
trial. Only a collaborative, synchronized evaluation can 
lead to the meticulous collection and sharing of the DNA/
RNA/Protein tissue analysis, that can lead to standardized 
selection of targets and therapeutic agent combinations, 
and where meticulous collection of the respective 
outcomes can be done.
The approach of this consortium has some 
similarities to the efforts extended by the ECOG-ACRIN 
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Cancer Research Group, NMTRC, SWOG, Alliance 
for Clinical Trials in Oncology, NRG Oncology Group 
and the multiple sites participating in the NCI National 
Clinical Trial Network for establishing the MATCH 
trial. But it differs, in its use of using bio-marker driven, 
molecularly-targeted metronomic combination therapy. 
The consortium(s) stresses the use of a multi-target, 
multi-modality approach rather than enrollment on single 
agent trials. The hope is that sufficient amount of data 
will be accumulated to provide the necessary evidence 
to inspire other organizations to extend the examination 
of tumor tissue to include genomic, proteomic and 
metabolomics examination of the host as well as of the 
tumor, and promote individualized cancer therapies. 
Because only a very small number of patients is going to 
have overlapping molecular alterations and as such require 
the same combination of agents, traditional population-
based statistical approaches comparing two disparately 
treated groups may not be applicable, and novel statistical 
approaches using predictive models of cancer growth are 
going to be needed. The data from all individual patients 
treated by a precision medicine approach will be stored in 
a single de-identified database to be shared not only with 
the consortium members but also with other clinicians and 
researchers interested in using targeted approaches. 
The additional benefit of sharing information 
of these N = 1 trials is going to be learning about the 
changed pharmacokinetics as combinations of different 
agents are being used. Pharmacokinetic studies are an 
integral part of present PhaseI/IV clinical trial structure. 
If we remove this resource, alternative experimental 
procedures that would allow for establishing clearance and 
biodistribution of these biologic agents will be needed. We 
will need to provide the clinicians with means to be able 
to quickly identify the key factors that govern absorption, 
distribution, metabolism, and excretion of the individual 
biologics, [32] the pharmacogenomics, [33], as well as the 
effect of using combinations of agents. Consideration will 
need to be given to developing new intelligence-enabled 
tools for quick dose adjustments if more than one cyp3a4 
or other members of the cytochrome P450 family involved 
in drug metabolism, are being used in the therapeutic 
regimen. 
The information collected would, in addition to 
traditional outcome measures such as survival, response, 
and toxicities, include information about quality of life and 
health care costs. The outcome database could thus be used 
to not only inform future selection of therapeutic agents 
and their combinations based on response, survival and 
toxicities, but also aid in formulating fiscally responsible 
clinical strategies based on cost-effectiveness models.[13] 
THE NEED TO PROVIDE AND 
INTERPRET LARGE AMOUNTS OF DATA 
WHILE MAINTAINING EXCELLENT 
DATA INTEGRITY
However brilliant the physician may be, there is no 
way he/she is going to remember the millions of possible 
genetic variants and what each of those variants may 
mean for the individual patient. Moreover, given our 
continuously evolving understanding of the genomics, 
proteomics, metabolomics and other characteristics of 
tumor growth, it is unrealistic to expect any individual to 
remain current and on top of new discoveries. Invariably, 
in order for physicians to access and make use of the vast 
and constantly emerging information, she/he will need to 
use a variety of computational tools, and have access to 
a well-maintained computational support infrastructure. 
While initially, the focus of this computational 
infrastructure may be on tumor genomic signatures, and 
on genomic backgrounds of the hosts, it should eventually 
incorporate for a true personalized medicine application 
all of the patient’s medical history, family history, dietary 
history, and exercise/activity information.
To implement precision medicine – and incorporate 
individual differences in genomic make-up and individual 
biological characteristics into treatment decisions – we 
will require the development and easy access to large-
scale genomic, proteomic, biologic and health information 
databases. While some protein-protein interaction (PPI) 
networks are already publicly available on the Internet, 
Figure 2: Pathway to combination targeted therapy 
design. The ability to evaluate outcomes of combination targeted 
therapies is dependent on the ability to standardize selection of 
therapeutic targets and low-dose metronomic backbones. The 
diagnosis of patient’s molecular profile should be based not 
only on the genomic analysis of the patient’s and the patient, but 
also on detecting the target proteins and their activation in the 
tissues. In order to incorporate, and consolidate the vast amount 
of information computer-assisted complex sociotechnical 
systems need to be employed to provide tumor boards with up-
to-date information about the best molecular targets. Finally, to 
continuously improve the quality of the information provided 
to tumor boards, AI should be used to inform future decisions. 
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they are, at least at present, mostly complex interaction 
maps developed by academic biologists over the last 50 
years. Of concern is that because they are maintained by 
academic institutions with varied levels of funding, they 
may be of varied levels of information integrity, and of 
different ability to integrate emerging information or 
to provide for any corrections/additions driven by new 
information. Due to the clear and potentially immediate 
impact precision medicine can exert on cancer therapies 
much of the information in these databases are dedicated 
to oncology. However, the long term goal should be to 
generate a broad ranging source of information about 
diseased and physiologic states that would be useable for 
general medical purposes. 
A POTENTIAL SOLUTION
To address the difficulty accessing, curating and 
interpreting large data, a clinician-relevant computer 
assisted search of available information of the publicly 
available databases needs to be created. While more 
information than ever is available to the clinician, the 
information is not only overwhelming, it is also dispersed 
across varied and copious sources, few of which are 
geared to clinical applications. Automated systems that 
can trawl, collect and align available relevant information 
and provide assistive interpretations for clinicians would 
significantly alleviate this problem. We can begin by 
accessing available information in publicly available 
academically or National Institute of Health curated 
databases and incorporate cancer knowledge networks 
as they become available. Such augmented human 
intelligence can improve the ability of an institutional 
tumor board to understand and interpret all of the available 
gamut of molecular information and remaining current on 
published medical information. 
The computerized system, containing a variety of 
artificial intelligence technologies can integrate a wide 
variety of information and apply an “understanding” 
of cancer biology in order to guide a tumor board in 
designing the most effective therapy for each of its unique 
patients. The system can do so by incorporating and 
cross-referencing information from multiple modalities, 
integrating this information in a clinical oncology 
context, and providing mathematical analysis of molecular 
pathways relevant to the patient’s specific (identified) 
molecular changes. The information incorporated into this 
stream can come not only from traditional academically 
curated databases, but also from medical and popular 
scientific literature sources, public media as well as health/
fitness tracking databases as recovered through social 
media. The information relevant to the individual patient 
can therefore superimposed onto a consolidated and highly 
cross-referenced informational stream providing the safest 
avenue for using the most up-to-date and continuously 
extended by emerging information. 
THE NEED TO DEVELOP NOVEL 
MATHEMATICAL APPROACHES 
FOR ESTABLISHING HIERARCHY 
OF GENOMIC ALTERATIONS IN 
INDIVIDUAL TUMOR SAMPLES
While the advent of genomic testing - whether by a 
panel of genes or the entire genome - offers tremendous 
potential in clinical decision-making. There is presently 
a dearth of choices in ways to interpret and apply the 
information to the clinic. Scientists and clinicians are 
besieged with methods for differentiating between 
driver genes and passenger genes, realizing that not all 
gene alterations detected in cancer tissues are of equal 
importance. The conservative approach has been to use 
an expert-approved panel of candidate oncogenes and 
tumor suppressor genes in clinical testing. However, 
most candidate gene panels test only for gene alterations 
well documented in the literature and other authoritative 
sources. Those targets are ‘assumed’ by experts to be 
necessary for cancer progression based on the fact 
that some of these candidate genes have been around 
for decades. They may be considered universal driver 
genes just by virtue of our familiarity with them and 
their commonness. While these candidate approaches 
help alleviate the information glut, they are based on 
insufficient information given our relative paucity and 
incomplete knowledge about the role genetic mutations 
may play in the host, in tumor specific host tissues, and/
or in cancer biology. While BRAFV600E and BRAFV600K 
mutations are established driver genes for neuroectodermal 
tumors such as melanoma, the use of BRAF fusions, and 
non BRAFV600E or non BRAFV600K gene alterations in 
gliomas will have to be established.[24, 34] 
To use and organize the continuously emerging and 
heterogeneous information being deposited into genomic 
(The Cancer Genome Atlas, TCGA; Gene Expression 
Omnibus, GEO; the NCI’s Database of Genomic Structural 
Variation; dbVar etc), proteomic (UniProt, Swiss-Prot end 
may others), and metabolomics (Kyoto Encyclopedia of 
Genes and Genomes, KEGG; and other) databases, as well 
as the concerted effort to identify and catalog genomic 
vulnerabilities across hundreds of cancer cell lines (Broad 
Institute’s Project Achilles), new computational tools for 
repeated and potentially automated analysis of large data 
sets need to be developed. 
A POTENTIAL SOLUTION
The impetus lies in improving the ability to select 
the most appropriate therapeutic target(s) for a particular 
patient. This necessitates development of novel approaches 
for large genomic or proteomic data analysis through 
multidisciplinary collaborations between mathematicians, 
physicists, statisticians, pharmacists, physicians, 
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bioinformaticians, artificial intelligence developers, 
biologists and software developers. The trans disciplinary 
process is mandatory in order to cover the end-to-end 
process, from cancer diagnosis, to testing for genomic 
alterations, to selecting appropriate targets, to analyzing 
pathways involved in cancer progression, to the design 
and administration of therapies. The motivation should 
be improving the ability to select the most appropriate 
therapeutic target(s) for a particular patient. 
There are two approaches to this. The first is 
more established and uses high-throughput statistical 
analysis (bioinformatics) of genomic data such as mRNA 
transcriptomes or RNA Seq from tumors of a population 
of patients with the same disease.[35-39] This approach 
provides the means to identify the most frequent genetic 
alterations in a population. The alternative approach 
applies novel mathematical and physical methods to 
determine how the individual patient compares to the 
genomic information derived from the population studies.
[40, 41] While it is expected that both approaches will 
merge in the not too distant future, they remain distinct at 
present and exist in two separate solitudes. Yet, in order 
to base a treatment decision on the unique molecular 
signature of the patient’s tumor, an a priori resolution of 
the detected molecular alterations using both methods is 
an absolute starting point for the process.
One previously described novel physical method 
for prioritization of targets applies a thermodynamic 
interpretation to gene expression, and then uses a 
topological filter to identify a set of potential therapeutic 
targets by their predicted effect on survival.[42, 43] 
The method makes use of publically available protein-
protein interaction networks (PPI networks). These 
PPIs are online repositories of interaction datasets 
compiled by international teams of academicians and 
researchers, and comprehensively curated into networks 
akin to telecommunication or social network maps. The 
thermodynamic entropy method considers these PPI 
networks a closed system where all interactions tend to 
equilibrium, and where entropy is a measure of the PPI 
network disorder. Because degree entropy of PPI networks 
for different cancers, correlates with likelihood of survival 
of patients with this cancer,[43] one can calculate the 
effect of eliminating a specific target (or eliminating 
multiple targets). This approach has demonstrated 
promising results, and points to the benefits arising from 
incorporating multidisciplinary perspectives to cancer 
models.
Another previously described method performs 
a pan-cancer analysis of mutated networks.[44] This 
unbiased and open-ended analysis had revealed 16 
significantly mutated subnetworks that were not 
previously thought to play significant role in cancer, and 
demonstrated that rare combinations of mutations, across 
multiple PPI networks may provide new insights and 
new opportunities for diagnostics and therapeutics across 
cancer types.
The PPI approach can be used in a number of ways. 
For instance, one can overlay transcriptional data from a 
single patient onto a PPI network, or a data set from The 
Cancer Genome Atlas (TCGA). As an example of the later, 
TCGA transcription data from a population of patients 
with glioblastoma multiforme (GBM) was overlaid on 
the BioGrid PPI network. The current Biogrid Index[45, 
46] version 3.3.124 (http://thebiogrid.org/), holds more 
than 820,000 protein interactions derived from high-
throughput datasets, individual focused experiments, 
and from over 44,000 publications. The types of protein-
protein interactions include actual chemical bonding, or 
temporary bonds known as secondary bonding, and the 
concentration of the specific proteins dictates the degree 
of interaction. If a protein is in limited supply, it is said 
to have low chemical potential, and if it is abundant, it is 
said to have high chemical potential. Thus, using protein 
concentration, we can calculate the chemical potential 
of each protein in the network (i.e. Gibbs free energy), 
compute a topological measure known as filtration 
threshold (an energy threshold), and “filter out” the most 
energetic subnetworks from the larger network and try to 
reduce complexity of these subnetworks by inhibiting each 
protein in turn. Using this strategy, the “best therapeutic 
targets” are those that, when inhibited, most effectively 
reduce the complexity of a PPI network.
As an alternative, one can superimpose patient-
specific tumor mRNA transcription data (a surrogate for 
protein concentration) onto BioGrid, calculate Gibbs free 
energy for all proteins in the network, and identify those 
nodes with most effect on entropy. Many of these nodes 
may not have been identified in the specific tumor type. 
For example, BRACA1, an accepted therapeutic target in 
breast or ovarian cancer, was identified as best therapeutic 
target for 41 out of 342 glioblastoma multiforme (GBM) 
patients in TCGA,[47] even though the importance of its 
overexpression in GBM is unknown. Similarly SIN3 was 
important in 38 of the 342 GBM patients in TCGA, and 
SIN3 turns out to be a member of a regulatory complex 
in the biology of glioblastoma.[48] A total of 46 unique 
targets were identified using GBM transcription data from 
342 patients with glioma available in TCGA.
The complex sociotechnical system[49] considered 
here should be designed to work with as much genetic, 
proteomic and biologic information as available, and 
involve as many fields of expertise as possible. It 
should be noted, that even though it is being designed 
for maximum efficacy in cancer (both solid tumors and 
leukemias/lymphomas), it can be broadened to cardiology, 
inflammatory bowel disease and other medical specialties 
as genomic information in these fields emerges. It is 
able to use full transcription information from the tumor 
tissue; subtractive transcription information of tumor 
tissue and patient normal tissue; proteomic analysis of the 
same; phosphorylation maps, methylation arrays etc. At 
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a minimum, it requires genetic information in the form 
of gene expression (transcription) microarrays or a panel 
of genes. Its strength lies in being able to continuously 
incorporate new information, as well as new mathematical 
and thermodynamic methods for therapeutic target 
prediction. 
THE NEED TO PROVIDE COMBINATION 
THERAPIES BASED ON PATHWAY 
ANALYSIS
Treatment decisions are, at least in present oncology 
practice, made on the basis of histological diagnosis, site of 
tumor origin (breast, lung, prostate etc), and the familiarity 
of the oncologist with a therapeutic agent. Despite the 
documented genetic and biological differences in even 
histologically identical site-specific cancer types,[8] 
most first line therapies do not diverge from the National 
Comprehensive Cancer Network (NCCN) Guidelines 
for Treatment of Cancer and national guidelines in other 
countries by site. They do not incorporate RNA/DNA 
sequence, transcription or protein expression information. 
Despite the evidence that molecular signatures of 
seemingly diverse and distinct cancers (lung squamous, 
head and neck, and a subset of bladder cancers) can 
coalesce into a common, site-independent molecular 
subtype,[50] most patients are still treated according to 
cancer site specific protocols. If considered, new treatment 
modalities are used only in second or later line of therapy, 
when additional molecular changes may have been added 
to the cancer initiating event adding to the complexity of 
controlling cancer growth. 
It is encouraging, however, that more and more 
oncologists are looking for safe and rational ways to 
incorporate genomic and biological information into first 
line therapies and individualize treatment protocols. This 
is especially true for oncologists treating patients with 
poor prognoses cancers such as sarcomas or brain tumors. 
But the approaches differ widely. The phrase “precision 
medicine” or “targeted therapies” are employed to describe 
a wide range of approaches in clinical oncology such as:
1. Targeted therapies used because a specific, 
single molecule is presumed to be present on the basis of 
previously published data (populational approach).
2. Therapies where, based on the histology of the 
tumor, a specific molecular target is looked for, identified 
and, if the mutation is present, treated as part of a single 
agent trial (a candidate target approach).
3. Targeted therapies that test for a panel of 
candidate molecules (usually an expert established panel 
of genes), but where a single target, selected either on 
the basis of its availability in a clinical trial, or on the 
availability of an FDA approved drug, is used (a panel of 
candidate targets approach).
4. Therapies that test the entire genome or 
transcriptome of the tumor and/or of the patient, but where 
a single molecular target is selected and treated.
5. Therapies that test the entire transcriptome and/or 
proteome and/or exome (note that the candidate approach 
is a subset of the full exome), a combination of molecular 
targets according to the ‘pathway activation strategy’ is 
selected, and all targets contributing to tumor progression 
are treated (the position of the authors).
It should be stressed, that using targeted agents 
in absence of testing for molecular alterations may be 
detrimental.[12] A recent comparison of outcomes of 
patients treated with targeted agents without testing 
the tumor tissues for targets (i.e. non-personalized 
targeted therapies) was associated with significantly 
poorer outcomes than even traditional cytotoxic agents 
approaches.[12]. The same comprehensive analysis 
of phase II, single-agent arms revealed that, across 
malignancies, a personalized strategy was an independent 
predictor of better outcomes and fewer toxic deaths[12] 
Similarly, using strategies that do not use combination 
therapies and thus do not inhibit the majority of molecular 
pathways contributing to tumor progression (the single 
agent approach) also provide no benefit.[51] The 
SHIVA prospective randomized trial[51-53] compared 
a personalized approach with conventional therapy in 
relapsed refractory adult solid tumors. This was a single-
agent treatment enrolling patients on the basis of limited 
molecular profiling of known targetable pathways, and 
it was not surprising that there was no difference in 
progression-free survival between the molecular alteration 
based therapy and conventional treatment. There may be 
more than one reason for the reduced efficacy of a single 
agent approach. There is a high likelihood of missing 
some important targets due to limited molecular profiling, 
and there is a high likelihood of treatment resistance due 
to alternative pathways with single agent approach. The 
use of several molecularly targeted agents in combination 
with low dose chemotherapy based on comprehensive 
analysis of individual tumor biology is an appealing way 
to counteract this type of treatment resistance.
The incorporation of tumor molecular signatures 
information into clinical practice has not been easy, 
and for most physicians the most acceptable manner 
of using tumor molecular signature information is 
to screen for commonly occurring alterations and to 
enroll the patient on a clinical trial using the particular 
inhibitor. While this may be a practical and rational 
solution, the approach is inadequate for patients with 
complex genomic signatures consisting of more than 
one gene alteration. With the exception of chronic 
myeloid leukemia (CML), gastrointestinal stromal tumor 
(GIST), dermatofibrosarcoma protruberans (DFSP), 
or other similarly rare cancers, single mutations rarely 
account for the complexity of cancer biology, or for 
the secondary gene activation(s) caused by alterations 
within the tumor microenvironment. The protection of 
cells from xenobiotic such as cytotoxic agents do not 
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require a mutation, commonly an increased expression 
(or activation) of molecular pathways already encoded in 
the genome is sufficient for emergence of resistant clone. 
As such targeting a single gene alterations is unlikely to 
be effective in most tumors. As one pathway is inhibited, 
an alternate pathway is activated or additional genomic 
alterations are acquired. 
A good example is provided in targeted treatment 
of melanoma using monotherapy. Treatment with either 
vemurafenib (BRAF inhibitor) or trametinib (MEK 
inhibitor) alone can lead to excellent, but invariably short-
lasting responses [54, 55] due to feedback activation 
of other pathways.[56-58] Because most oncogenic 
changes tend to hijack physiologic host responses such 
as inflammation, nullify other host defense mechanisms 
such as immune surveillance, and/or re-activate dormant 
developmental pathways for angiogenesis, immune 
evasion, and growth – the feedback loops are endless. 
Because oncogenic BRAFV600E can lead to melanoma 
cancer cell immune evasion,[59] and the reversal of this 
evasion by addition of PD1 or CTLA4 immunologic 
therapies has been shown to provide additional benefit 
to BRAF inhibition alone. The combination of immune 
checkpoint inhibitors and BRAF-targeted agents 
in melanoma suggests a synergistic action of these 
otherwise independent therapeutic modalities,[60, 61] 
and a much longer response duration. While there may 
be a specific genomic signature that corresponds to 
immune evasion,[62] the use of combination therapy 
using inhibitors of BRAF, MEK and immune checkpoint 
inhibitors has caused 2-year survival rates of patients with 
metastatic melanoma to rise to 79%.[63]
A POTENTIAL SOLUTION
A potential solution to managing the information 
glut and helping the oncologist to provide patients with the 
right combination of targeted agents and chemotherapy, 
is to enable them to use all of the available information. 
While producing complete genomic, proteomic and 
metabolomics datasets for each patient is not feasible at 
present, it has been possible in some well-funded research 
units to access the entire tumor and host transcriptomic 
information. The more complete the information provided 
for the analysis of the involved pathway(s), the more 
complete the therapeutic coverage. Unfortunately, for 
most physicians practicing clinical oncology today, the 
most feasible option is using a panel of candidate genes, 
because this may be covered by the patient’s insurance. 
At lease in the US, clinical ‘omic’ testing is restricted to 
genomic panels through CLIA certified laboratories. Even 
though this approach carries the inherent risk that some 
driver genes may not be identified, and thus not included 
in therapy, it is a good initiating step towards the future. 
The complex sociotechnical system being deployed 
by the authors of this manuscript maps the available 
molecular information from patients’ tumors onto an 
oncology interpretation knowledge base pooled and 
cross-referenced from multiple sources, and weighted in 
PPI networks according to the unique composition of the 
patient’s distinctive molecular signature. The combination 
of genetic alterations and mutational variants are matched 
to a series of filtered (see above) PPI subnetworks 
corresponding to biologic pathways relevant to cancer 
growth and progression, thus identifying molecular lesions 
that can be targeted with therapeutic intent. This complex 
sociotechnical system then searches the available literature 
and other reliable resources to find therapeutic agents 
targeting the identified molecular lesion(s), and minimize 
the number of drugs needed to inhibit all pathways within 
the identified PPI subnetwork. The system also considers 
the topology and interaction of each of the identified 
anomalous pathways in order to use the minimum possible 
drugs, and still achieve the same therapeutic result. in 
situations where specific genomic alterations may confer 
an a priori resistance to a therapeutic agent,[64, 65] the 
agent is eliminated. 
Roughly similar to the current use of Artificial 
Intelligence technologies deployed in recommending 
movies on the basis of our previous choices, likes or 
dislikes, one of the AI components in this system records 
and documents the selection of targets, the treatment 
protocols and the respective outcomes in order to inform 
future therapeutic selections. More specifically, as 
oncologists and other experts on the tumor board introduce 
novel evidence for, or arguments against a therapeutic 
choice provided by the system, the information is 
recorded and used to refine future pathway analyses. The 
hope is that genomic/proteomic information will become 
affordable and we will include the genomic/proteomic 
analysis as a standard component of the electronic medical 
record. In turn, as more information from patient’s medical 
record is incorporated, we will be able to consider any 
co-morbid conditions of the host and filter out harmful 
or ineffective drugs from the therapy recommendations 
further, resulting in improvement of the safety of our 
treatments. 
THE NEED TO AVOID COMBINATIONS 
WITH MAXIMUM TOLERATED DOSES 
OF CHEMOTHERAPY: THE ARGUMENT 
FOR LOW DOSE (METRONOMIC) 
CHEMOTHERAPY BACKBONE
A commonly employed approach for enhancing 
the ability chemotherapy to fight cancer is to use 
chemotherapy in combination with a biological agent. 
An assumption is made that the inhibitory effect of the 
biological agent would be additive to the effect achieved 
by traditional chemotherapy or radiation. However, 
the use of biologic agents, especially those inhibiting 
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host responses (such as angiogenesis or inflammation), 
strip the anomalous cells (but also the patient’s normal 
cells) of its defense mechanisms such as growth factors 
and inflammatory cytokines and lead to sensitization of 
all cells to DNA damaging agents such as radiation or 
chemotherapy. Because most mechanisms used to protect 
cells from xenobiota such as chemotherapy or radiation 
tend to activate developmental pathways already encoded 
in the genome, inhibition of these pathways increases 
toxicities whenever standard (maximum tolerated) doses 
of chemotherapy or radiation are used with biological 
agents.[66] 
In a standard clinical trial, where a standard arm 
is compared to standard arm with the biological agent, 
the approach greatly disadvantages the intervention arm. 
The combination of the biologic agent and high dose 
chemotherapy, makes an already maximally toxic regimen 
lethal. As a result, the benefit of any tumor response will 
be concealed by these increased toxicities, and no overall 
survival benefit will be seen.[66] An example of this is 
the case of combining bevacizumab with standard MTD 
chemotherapy. While the RIBBON2 trial showed an 
improved progression-free survival compared to patients 
treated only with chemotherapy alone [PPS 7.2 months 
in the experimental group compared to 5.1 months 
in the chemotherapy only arm (p - .0072)]. The 10% 
improvement in overall survival rate was not statistically 
significant.[67] Based on this finding, the US Food and 
Drug Administration (FDA) revoked the approval of 
bevacizumab as a first line treatment for breast cancer, 
even though the majority of women had responded, and 
some remain well controlled on the drug to date. 
The concept of “metronomic chemotherapy” was 
initially introduced in the year 2000,[29, 68, 69] and 
constituted a marked departure from the classic model 
of maximum tolerated dose (MTD) strategy. It emerged 
in the face of early clinical and pre-clinical evidence 
supporting its ability to suppress tumor growth even in 
cases where the cancer cell was resistant to the MTD 
of the used chemotherapeutic agent.[29, 68, 70, 71] 
Unfortunately, the concepts were poorly understood 
and underused. It has gained momentum however and 
at present it is being adopted with increasing frequency 
around the world,[72-74] and the website www.
clinicaltrials.org now lists over 150 trials that use the word 
“metronomic” in their title. The mechanism of action of 
metronomic chemotherapy has been subject to excellent 
recent reviews,[75] and its value to implementation of 
precision medicine well documented.[22] To summarize 
briefly, because of the side effects induced by maximally 
dosed chemotherapy, the duration of the therapy has to be 
limited and breaks for bone marrow recovery incorporated. 
Furthermore, because conventional chemotherapy targets 
only proliferating malignant cells, a large portion of 
malignant cells is not affected. Only once these cells are 
re-engaged in the cell cycle process cytotoxic drugs are 
able to corrode them. Metronomic therapy implies that 
the use of low, continuous doses of chemotherapy in 
combination with biologic response modifiers not only 
avoid toxic side effects, but also preferentially target the 
host biological responses such as stromal induction,[76] 
angiogenesis,[68, 77, 78] immune surveillance,[75, 79, 
80] and inflammation.[76] Angiogenesis and inflammation 
represent a physiological repair mechanisms hijacked by 
the proliferating tumor and actively contributing to tumor 
cell re-growth. The enormous success in the treatment of 
pediatric acute lymphoblastic leukemia, is at least partially 
due to the one and a half year long maintenance low dose 
metronomic chemotherapy. 
Thus, it should be stated that in cases where up-
front eradication of the cancer is not possible with MTDs, 
the MTD-induced up regulation of host inflammatory 
responses, rather than defending us from cancer, 
contributes to subsequent cancer progression. Because 
MTD chemotherapy kills only chemo-sensitive cells with 
each cycle, the chance of selection of a chemotherapy 
resistant subpopulation and recurrence is very high. 
Metronomic chemotherapy, with its goal of long-
term “tumor control”, lower toxicity, and prevention of 
tumor progression (rather than immediate reduction in 
tumor size), may represent a more realistic strategy for 
cancer therapy. This is especially true for cancers not 
amenable to upfront cancer eradication. While slower 
in its onset of action (see Figure 3), metronomic dosing 
has demonstrated better long term tumor control, even 
for cancers rendered resistant to the same drug under 
MTD,[29, 68, 78] because the low-dose chemotherapy 
approach avoids selection of a resistant cancer cell 
population. 
A very strong argument for the use of a metronomic 
chemotherapeutic backbone in combination with targeted 
therapies is the risk of metastatic growth.[81, 82] This 
risk of exacerbating metastases has however, only been 
documented with single agent therapy and only in pre-
clinical murine models. It remains theoretical in clinical 
practice where it is usually prevented by the synergistic 
action of biologic agents and low dose chemotherapy. 
The same is true for avoiding emergence of therapeutic 
resistance with targeted agents alone.[57] 
A POTENTIAL SOLUTION
In the coming decade(s) a background for the 
combination therapies will be applied for any patients with 
chemotherapy resistant cancer or for patients with very 
poor prognosis. As much information as possible should 
be gathered about the patient’s tumor molecular signature, 
about the host specific germline gene alterations, and about 
the host phenotype as soon as possible, so as to avoid 
unnecessary toxicities and delays with standard therapies 
whenever success cannot be reasonable expectation. The 
hope is that data from each of these cases will be collected 
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and each of the individual outcomes will inform any future 
therapeutic decision. 
CASE 1
A previously healthy 11 year old girl with 
neurofibromatosis type 1 was diagnosed in 2011 with a 
large right parietal glioblastoma multiforme following an 
episode of left sided weakness. She was found to have 
a hemorrhagic stroke, and despite a partial resection of 
the tumor, her hemiparesis never resolved. She was 
started on COG ACNS0822, randomized to Arm A, and 
she completed the 6 weeks of radiation and vorinostat. In 
November 2011 she started maintenance chemotherapy 
with Avastin 10mg/kg Day 1 and 14/ Temozolomide 
200mg/m2 Days 1-5 for 28 day cycle. She completed 11 
out of 12 cycles before coming off protocol for disease 
progression in October 2012. 
She was started on melatonin, metformin, 
cyclophosphamide and erlotinib based on a proteomic 
analysis done at Texas Children’s. She progressed again 
within 2 months with leptomeningeal spread to the 
spine, and was changed to VP-16, vincristine, crizotinib, 
erlotinib, vorinostat. The regimen resulted in unacceptable 
toxicities with myelosupression, severe mucositis, and 
QTc prolongation with cardiac compromise. 
She was taken off any disease directed therapy in 
March 2013 and referred to us for molecular analysis 
and individualized therapy. The characteristics of the 
tumor at diagnosis showed activation of a number of 
pathways associated with cancer growth and progression. 
The findings and initial pathology are summarized in 
Figure 4. The genomic analysis revealed NF1 R1968*, 
BRCA1 N1355fs*10, CDK4 amplification, TP53 R175H, 
SOX2 amplification. Because loss of neurofibromin 
function leads to increase in signaling through the Ras-
Raf-MAPK and mTOR pathways, [83] she was started 
on sirolimus 2mg daily and sorafenib to inhibit growth 
factors downstream from these pathways in addition to 
metronomic (50 mg/m2) etoposide daily. She remained 
stable on this regimen until December 2015 (3 years) 
when she had a radiological progression. 
She underwent an excisional biopsy and the 
molecular analysis of this relapse was consistent with 
a radiologically, histologically and genetically more 
aggressive phenotype (Figure 4). In addition to the original 
gene alterations, she now had BRCA2 splice site 67+1G > 
A, ERBB3 S1074N, TSC1 splice site 364-1G > A, GLI1 
amplification, STAG2 Q1167*. Her therapy was therefore 
changed to everolimus (Ras-Raf-MAPK and mTOR 
pathways), ceritinib (GLI1/sonic Hedgehog pathway), and 
trametinib on a metronomic chemotherapy backbone of 
temozolomide 25 mg/m2, and remains stable. 
The case provides a good illustration about the need 
for multi-agent therapy based on molecular signature. 
It also stresses the need to consider re-biopsy with 
relapse as the eco-evolutionary forces within the tumor 
microenvironment may cause therapeutic resistance and 
escape from tumor dormancy.[84]
CASE 2
A 7-y old previously healthy boy with no family 
history of cancer was diagnosed with stage III abdominal 
Burkitt lymphoma in December 2014. He was initially 
treated standard BFM B-NHL 04 therapy, which 
Figure 3: Comparison of Metronomic and Standard dose strategies. The onset of action of metronomic chemotherapy is 
slower, but because of its ability to suppress biological processes such as angiogenesis or inflammation which are often “hijacked” by the 
tumor for growth, and because it avoids selection of the resistant population of cells, its effects are more sustained. However if comparison 
of these two therapies is made before 6 months, the wrong conclusion about the effectiveness of metronomic chemotherapy may be made. 
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included a single initial dose of 375mg/m2 Rituximab 
followed with 5 cycles of BNHL 04 chemotherapy 
consisting of dexamethasone, methotrexate, ifosfamide, 
cyclophosfamide, cytarabine, etoposide, doxorubicine, 
vincristine as well as intrathecal therapy. After 2 cycles, 
he had a very good partial response reaching < 5% of 
the initial tumor volume. An episode of the intestinal 
obstruction in February 2015 led to excision, and the 
histology confirmed sclerosing mesenteritis, without 
histological or rtPCR evidence of lymphoma (the original 
tissue was positive for cMYC translocation). The FDG 
PET was borderline positive, but this was thought to be 
due to inflammation.
Unfortunately the child was found to have an 
isolated radiological progression in the same region in 
which the intestinal obstruction had occurred two months 
after completing chemotherapy. The biopsy in June 2015 
confirmed relapsed Burkitt lymphoma, this time with 
marked areas of sclerosing mesenteritis and mesenteric 
panniculitis. Mutational analysis of PI3K delta subunit 
proved germinal mutation/variant outside the classical 
Activated PI3K-delta syndrome (APDS) 1 or 2 variants. 
The mutational activation was confirmed by testing 
the patient’s T- lymphocytes, and the S6 (Ser235/236) 
phosphorylation was found to be 33 fold that of a healthy 
control. 
While undergoing the genomic testing, the boy was 
started on retrieval therapy with ibrutinib, obinutuzumab 
and ICE chemotherapy. Unfortunately, after a transient 
response and disease stabilization, he had an early 
progression following the first cycle. Based on the finding 
of germline mutation in PI3K delta subunit, he got 2 
weeks of idelalisib (a phosphoinositide 3-kinase inhibitor, 
which blocks P110δ, the delta isoform of the enzyme 
phosphoinositide 3-kinase). The single agent therapy led 
to normalization of the S6 (Ser235/236) phosphorylation 
in patients peripheral T lymphocytes, but he had further 
disease progression. It was only when the combination of 
high dose cytarabine/ etoposide (CyVe) with idelalisib and 
obinutuzumab was used that the disease was stabilized. 
A biopsy on 9/2015 showed a CD20 positive tumor, with 
high degree of proliferation and strong expression of PD-
1L. 
The second biopsy was analyzed using Affy 
GeneChip ST 1.0 and the whole transcriptome analysis 
confirmed increased levels of PI3K and revealed 
additional HR23B. Because HR23B can be used as a good 
predictor of response to HDAC inhibitors, valproic acid 
was being considered. Additional tumor specific (somatic) 
gene alterations in R273C and p53 were also shown. 
The child, who had continued on oral ibrutinib + 
idelalisib and low dose cyclophosphamide since 9/2015, 
received palliative 21Gy local radiation. In 10/2015, based 
on the second biopsy findings, the nivolumab, a human 
IgG4 anti-PD-1 monoclonal antibody, and valproic acid, 
and HDAC inhibitor, were added. As of March 2016 the 
boy is doing very well. He has had partial response of 
the single residual abdominal tumor disease, and remains 
clinically well with Lansky score 100 and OS > 15 months. 
He comes to clinic biweekly for nivolumab infusions and 
assessments, but remains outpatient otherwise. He started 
his personalized therapy after his second relapse, and this 
3rd EFS (7 months) is already the longest EFS, compared 
to 6 months post his initial standard BFM protocol and 
just 1 month post ibrutinib, obinutuzumab and ICE 
chemotherapy.
The case may illustrate a new variant of Activated 
PI3K-delta syndrome (APDS). At least at present the 
disease is not tested for and generally not recognized 
in children with Burkitt’s lymphoma. Even if this child 
had a family history supporting testing for the autosomal 
dominant form of APDS, he would not have been found. 
Yet, he had an atypical germinal mutation in the gene that 
leads to lymphoid hyperplasia, and increases the risk of 
malignant transformation to B-cell lymphoma. The p110δ 
protein is a crucial subunit of the PI3K enzyme, and 
regulates activation of proliferative pathways in B-cells. 
As such, unless this constitutional activation can be 
blocked, it will be unlikely that 5 cycles of conventional 
chemotherapy could successfully prevent a relapse. It 
may be prudent, in cases where a mutational activation 
of an important proliferative pathway is found, to use 
maintenance biological therapy. This could be similar to 
the 2 years maintenance therapy used in childhood Acute 
Lymphoblastic Leukemia, which has cure rates of about 
90%. It is our hope that this case illustrates a potential 
for keeping even children with poor prognosis due to 
genetically complex cancers at home. While not able to 
eradicate the cancer or it causative mutation, we may be 
able to keep them well, in school and active by prescribing 
a combination of low-dose metronomic chemotherapy, an 
immune checkpoint inhibitor, and a direct inhibitor of the 
activated pathway(s).
SUMMARY
Many oncologists treating recurrent, chemotherapy 
resistant or poor prognosis cancers have begun re-
purposing anti-inflammatory agents or immune 
modulators. Similarly, many oncologist use direct 
anticancer agents in an off-label setting to target specific 
genomic mutations regardless of the cancer subtype. An 
equal number of oncologists however, due to the time 
required for researching the vast amount of molecular 
information, continue treating children with conventional 
therapies. But for those cancers where the present 
chemotherapeutic, surgical and radiation strategies fail 
– the option of targeted strategies should be strongly 
considered. 
The difficulty is that physicians using targeted 
therapies today do so without the benefit of computational 
infrastructure. While we use complex sociotechnical 
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Figure 4: Histology of case 1, glioblastoma progression. The original right temporal mass resected in 2011 showed glial neoplasm 
with vascular proliferation, necrosis, mitosis, and numerous pleomorphic cells, including rare giant cells. At this time, there was strong and 
diffuse immunopositivity for GFAP, and markedly elevated Ki-67 proliferative index, consistent with Glioblastoma WHO grade IV/IV. The 
original lesion regressed after the initial targeted therapy with sirolimus, sorafenib and metronomic VP16, but relapsed with a new extra 
axial lesion. The relapsed tissue in 2015 showed glial neoplasm with numerous tumor giant cell and atypical mitoe. The tumor cells were 
immunonegative for NEU-N, IDH-1(R132H) and BRAFv600E, but the molecular signature had obviously evolved, adding further genomic 
alterations. At this time, the tumor was negative for GFAP, and the ganglional component was no longer present. Both the 2011 and 2015 
specimens had shown increased lymphocytic component and myxoid background, along with tumor giant cells, but the number of giant 
cells was increased significantly in the 2015 specimen.
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systems to manage nuclear plants and airports, we have 
not developed similar systems for the analysis and 
application of omics information. We need an efficient 
complex sociotechnical system that would allow us to 
analyze a molecular signature of the patient’s cancer in 
minutes and select the appropriate molecular agent(s) in 
time for effective therapy. 
We also need to abandon the present model of 
drug development. The present process often takes 
decades for each of the new therapeutic agents. Millions 
are spent testing each of the agents in individual Phase 
I-IV trials before its introduction to the clinic resulting 
in cost-prohibitive therapies. Most importantly however, 
thousands of patient lives are lost as we struggle to 
determine whether an agent “is clinically active” in 
the incorrectly designed clinical trials. A wealth of 
bioinformatics resources exists that can help narrow 
the choice of therapeutic combinations from the wide 
selection of already available molecular agents, and 
provide a treatment for a wide range of difficult to treat 
cancers TODAY. 
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